<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602744</url>
  </required_header>
  <id_info>
    <org_study_id>0036-12 WOMC</org_study_id>
    <nct_id>NCT01602744</nct_id>
  </id_info>
  <brief_title>The Use of STOPP/START Criteria for Medication Intervention Among Elderly Population Living in a Geriatric Hospital</brief_title>
  <acronym>STOPP</acronym>
  <official_title>The Use of STOPP/START Criteria for Medication Intervention and the Risk of Falls, Hospitalization, Functioning and Quality of Life Among Elderly Population Living in a Geriatric Hospital in Israel and Comparison to Beers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Wolfson Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Wolfson Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if the use of STOPP/START criteria (STOPP-screening
      tool of older persons potentially inappropriate prescriptions START-screening tool to alert
      doctors to right treatment)for medication intervention in elderly population living in a
      geriatric hospital will lower the number of falls,hospitalization,will improve functioning,
      quality of life and reduce financial costs.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inappropriate prescribing is common in older people and is associated with adverse drug
      effects,hospitalization and falls. In this trial we want to check the efficacy of the
      screening tools STOPP/START which were developed and validated in order to reduce
      inappropriate prescribing. STOPP comprises of 65 indicators of drug-drug, drug-disease
      interactions and therapeutic duplication. START incorporates 22 evidence based indicators of
      common prescribing omissions. We will conduct a randomized controlled trial to test the
      hypothesis that screening the medications of older patients living permanently in a geriatric
      hospital will improve their quality of life. The compliance of the doctor working in the
      geriatric hospital to the recommendations of the screening tools will also be checked.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Life- Mental Component Summaty (MCS)</measure>
    <time_frame>Outcome measures were assessed at the end of the 12 month follow up</time_frame>
    <description>Quality of life will be measured by MOS SF-12 Health Survey questionnare. Results are expressed in terms of two meta scores: The Physical Component Summary(PCS) and the Mental Component Summary (MCS). The PCS and MCS scores have a range of 0 to 100, thus scores greater than 50 represent a better than average health status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SF-12 Health Survey questionnaire-the Physical Component Summary (PCS)</measure>
    <time_frame>Outcome measures were assessed at the end of the 12 month follow up</time_frame>
    <description>Quality of life was assessed by the SF-12 Health Survey questionnare. Results are expressed in terms of two meta scores:the Physical Component Summary (PCS) AND Mental Component Summary (MCS). The PCS and MCS scores have a range of 0 to 100, thus scores greater than 50 represent a better than average health status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Falls</measure>
    <time_frame>At the end of the 12 month follow up</time_frame>
    <description>Average number of falls per year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>Outcome measures were assessed at the end of the 12 month follow up</time_frame>
    <description>The average number of hospitalizations per year.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Functional Independence Measure (FIM)</measure>
    <time_frame>Outcome measures were assessed at the end of the 12 month follow up</time_frame>
    <description>Functioning was assessed by the FIM score. The FIM rates 18 activities of daily living on a 7 point scale ranging from fully dependent (=1) to independent (=7). A maximum score of 126 indicates functional independence and the lowest score of 18 indicates functional dependence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacoeconomics Analysis-Costs of Medication</measure>
    <time_frame>Outcome measures were assessed at the end of the 12 month follow up</time_frame>
    <description>The costs on medications in the geriatric hospital before and after intervention e.g. pharmaeconomic analysis of the intervention. Costs of medications were calculated in New Israeli shekels per month and taken from the Ministry of Health's medication price list.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">382</enrollment>
  <condition>Adverse Drug Effects</condition>
  <arm_group>
    <arm_group_label>Controll</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The medications in this arm will not be screened.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention screening medication group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>STOPP/START screening tools are used for medication intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>STOPP/START screening tools for medication intervention</intervention_name>
    <description>In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.</description>
    <arm_group_label>Intervention screening medication group</arm_group_label>
    <other_name>STOPP Criteria</other_name>
    <other_name>START Criteria</other_name>
    <other_name>medication intervention</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age over 65

          -  live in the geriatric hospital &quot;Givaat Hashlosha&quot; permanently.

        Exclusion Criteria:

          -  people with a terminal illness that will not live more than a year.

          -  people who enter the geriatric hospital for a short while (are not permanent).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ariella Herskowits, MBA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolfson Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Givaat Hashlosha Geriatric Hospital</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2012</study_first_submitted>
  <study_first_submitted_qc>May 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <results_first_submitted>November 24, 2013</results_first_submitted>
  <results_first_submitted_qc>January 23, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 12, 2014</results_first_posted>
  <last_update_submitted>March 23, 2014</last_update_submitted>
  <last_update_submitted_qc>March 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>STOPP screening tool</keyword>
  <keyword>START screening tool</keyword>
  <keyword>MIP-medication inappropriate prescription</keyword>
  <keyword>PIM-Potentially inappropriate medication</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Drug-Related Side Effects and Adverse Reactions</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Data were collected on April 2012 from 382 residents' records in &quot;Givaat Hashlosha&quot; geriatric facility.23 residents were excluded for not fulfilling study entry criteria. The final study group was comprised of 359 residents. 359 residents were randomized on May 2012 to recieve either STOPP/START screening (N=183) or usual care (n=176).</recruitment_details>
      <pre_assignment_details>23 residents were excluded: 10 were younger than 65 years of age, one was not taking medications, 5 had a terminal illness and 7 had been on a short stay in the facility.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Controll</title>
          <description>The medications in this arm will not be screened.</description>
        </group>
        <group group_id="P2">
          <title>Intervention STOPP/START</title>
          <description>Screening medications with STOPP/START critera</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="183"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="146"/>
                <participants group_id="P2" count="160"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All residents in the geriatric facility (382) were recruited for the trial. 23 were excluded for not fulfilling study entry criteria. The final study group was comprised of 359 residents. Residents were randomized to recieve either STOPP/START screening (intervention, n=183) or usual care (control, n=176).</population>
      <group_list>
        <group group_id="B1">
          <title>Controll</title>
          <description>The medications in this arm will not be screened.</description>
        </group>
        <group group_id="B2">
          <title>Intervention STOPP/START</title>
          <description>Screening medications with STOPP/START critera</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="176"/>
            <count group_id="B2" value="183"/>
            <count group_id="B3" value="359"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.2" spread="9.4"/>
                    <measurement group_id="B2" value="83.1" spread="7.99"/>
                    <measurement group_id="B3" value="82.7" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="110"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="120"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Israel</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="176"/>
                    <measurement group_id="B2" value="183"/>
                    <measurement group_id="B3" value="359"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Life- Mental Component Summaty (MCS)</title>
        <description>Quality of life will be measured by MOS SF-12 Health Survey questionnare. Results are expressed in terms of two meta scores: The Physical Component Summary(PCS) and the Mental Component Summary (MCS). The PCS and MCS scores have a range of 0 to 100, thus scores greater than 50 represent a better than average health status.</description>
        <time_frame>Outcome measures were assessed at the end of the 12 month follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Controll</title>
            <description>The medications in this arm will not be screened.</description>
          </group>
          <group group_id="O2">
            <title>Intervention STOPP/START</title>
            <description>Screening medications with STOPP/START critera</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life- Mental Component Summaty (MCS)</title>
          <description>Quality of life will be measured by MOS SF-12 Health Survey questionnare. Results are expressed in terms of two meta scores: The Physical Component Summary(PCS) and the Mental Component Summary (MCS). The PCS and MCS scores have a range of 0 to 100, thus scores greater than 50 represent a better than average health status.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.6" spread="11.3"/>
                    <measurement group_id="O2" value="37.7" spread="11.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacoeconomics Analysis-Costs of Medication</title>
        <description>The costs on medications in the geriatric hospital before and after intervention e.g. pharmaeconomic analysis of the intervention. Costs of medications were calculated in New Israeli shekels per month and taken from the Ministry of Health's medication price list.</description>
        <time_frame>Outcome measures were assessed at the end of the 12 month follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Controll</title>
            <description>The medications in this arm will not be screened.</description>
          </group>
          <group group_id="O2">
            <title>Intervention STOPP/START</title>
            <description>Screening medications with STOPP/START critera</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacoeconomics Analysis-Costs of Medication</title>
          <description>The costs on medications in the geriatric hospital before and after intervention e.g. pharmaeconomic analysis of the intervention. Costs of medications were calculated in New Israeli shekels per month and taken from the Ministry of Health's medication price list.</description>
          <units>New Israeli shekels per month</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402.3" spread="291.2"/>
                    <measurement group_id="O2" value="279" spread="171.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>SF-12 Health Survey questionnaire-the Physical Component Summary (PCS)</title>
        <description>Quality of life was assessed by the SF-12 Health Survey questionnare. Results are expressed in terms of two meta scores:the Physical Component Summary (PCS) AND Mental Component Summary (MCS). The PCS and MCS scores have a range of 0 to 100, thus scores greater than 50 represent a better than average health status.</description>
        <time_frame>Outcome measures were assessed at the end of the 12 month follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Controll</title>
            <description>The medications in this arm will not be screened.</description>
          </group>
          <group group_id="O2">
            <title>Intervention STOPP/START</title>
            <description>Screening medications with STOPP/START critera</description>
          </group>
        </group_list>
        <measure>
          <title>SF-12 Health Survey questionnaire-the Physical Component Summary (PCS)</title>
          <description>Quality of life was assessed by the SF-12 Health Survey questionnare. Results are expressed in terms of two meta scores:the Physical Component Summary (PCS) AND Mental Component Summary (MCS). The PCS and MCS scores have a range of 0 to 100, thus scores greater than 50 represent a better than average health status.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33" spread="8.3"/>
                    <measurement group_id="O2" value="33.1" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Falls</title>
        <description>Average number of falls per year.</description>
        <time_frame>At the end of the 12 month follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Controll</title>
            <description>The medications in this arm will not be screened.</description>
          </group>
          <group group_id="O2">
            <title>Intervention STOPP/START</title>
            <description>Screening medications with STOPP/START critera</description>
          </group>
        </group_list>
        <measure>
          <title>Falls</title>
          <description>Average number of falls per year.</description>
          <units>Number of falls per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.26" spread="2.4"/>
                    <measurement group_id="O2" value="0.8" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Hospitalizations</title>
        <description>The average number of hospitalizations per year.</description>
        <time_frame>Outcome measures were assessed at the end of the 12 month follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Controll</title>
            <description>The medications in this arm will not be screened.</description>
          </group>
          <group group_id="O2">
            <title>Intervention STOPP/START</title>
            <description>Screening medications with STOPP/START critera</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations</title>
          <description>The average number of hospitalizations per year.</description>
          <units>Number of hospitalizations per year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.47" spread="0.87"/>
                    <measurement group_id="O2" value="0.49" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Functional Independence Measure (FIM)</title>
        <description>Functioning was assessed by the FIM score. The FIM rates 18 activities of daily living on a 7 point scale ranging from fully dependent (=1) to independent (=7). A maximum score of 126 indicates functional independence and the lowest score of 18 indicates functional dependence.</description>
        <time_frame>Outcome measures were assessed at the end of the 12 month follow up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Controll</title>
            <description>The medications in this arm will not be screened.</description>
          </group>
          <group group_id="O2">
            <title>Intervention STOPP/START</title>
            <description>Screening medications with STOPP/START critera</description>
          </group>
        </group_list>
        <measure>
          <title>Functional Independence Measure (FIM)</title>
          <description>Functioning was assessed by the FIM score. The FIM rates 18 activities of daily living on a 7 point scale ranging from fully dependent (=1) to independent (=7). A maximum score of 126 indicates functional independence and the lowest score of 18 indicates functional dependence.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="146"/>
                <count group_id="O2" value="160"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.4" spread="36.8"/>
                    <measurement group_id="O2" value="54.3" spread="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One year of follow up.</time_frame>
      <desc>A daily follow up of the chief physician un the geriatric facility.</desc>
      <group_list>
        <group group_id="E1">
          <title>Controll</title>
          <description>The medications in this arm will not be screened.</description>
        </group>
        <group group_id="E2">
          <title>Intervention STOPP/START</title>
          <description>Screening medications with STOPP/START critera</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="183"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The limitations of the study were that it was conducted in a single geriatric center. This precludes the possibility of generalizing its findings to other older segments of the community.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dvora Frankenthal</name_or_title>
      <organization>Tel Aviv University</organization>
      <phone>0097235326835</phone>
      <email>shai_f@zahav.net.il</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

